Rena Patel, MD
Infectious Disease · Birmingham, ALNPI 1184909079
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,610 of the $2,932 with a category attached, or 89.0%. Gilead accounts for 89.0% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $2,868, more than ten times the $46 reported in 2023.
Across 16 payments — averaging $183.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- ARS Pharmaceuticals Operations, Inc.$225
- Blueprint Medicines Corporation$64
- CSL Behring$33
Across 3 payments — averaging $169,532 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$509K
What the payments were for
- Consulting fees$2,61089%
- Food & beverage$32211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $2,610 |
| ARS Pharmaceuticals Operations, Inc. | 12 | $225 |
| Blueprint Medicines Corporation | 2 | $64 |
| CSL Behring | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$2,610
How this compares
$2,932 in reported general payments places this provider in the 65th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 19 | $172 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Birmingham
- John BaddleyBirmingham$113K
- Christina MuznyBirmingham$111K
- Sonya HeathBirmingham$80K
- William GeislerBirmingham$63K
- Edward HookBirmingham$61K
- Edgar OvertonBirmingham$46K
- Jane SchwebkeBirmingham$42K
- Peter PappasBirmingham$25K
- Jeanne MarrazzoBirmingham$23K
- Todd McCartyBirmingham$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.